Store
In Vitro Diagnostics Business Outlook, 2026
Publication Date: January 29, 2026
Tags: Coagulation, COVID-19, Genetic Diseases, Hematology, Histology and Cytology, Immunoassay, In Vitro Diagnostics (IVD), Infectious Diseases, Molecular Diagnostics, Oncology and Cancer, Point-of-Care (POC) Testing
Pages: Varies (average 30 pages)
SKU: 26-014KA
The in vitro diagnostics (IVD) industry is a cornerstone of modern healthcare, empowering clinicians to detect disease, monitor health conditions, and guide treatment decisions with precision. As healthcare continues to evolve—driven by rising rates of chronic conditions such as diabetes and cardiovascular disease, along with ongoing and emerging infectious threats—the IVD market is undergoing constant change and growth.
In Vitro Diagnostics Business Outlook is a monthly intelligence publication designed to help industry professionals stay current in this fast-moving environment. Delivered in 12 issues annually, each issue focuses on a different segment of the IVD industry, providing timely insights, exclusive data, and in-depth analysis.
Featured Content
Each monthly issue provides:
-
Market Data and Forecasts
Detailed growth rates, market size, and market share to help identify emerging opportunities. -
Comprehensive Market View
Coverage of key test categories and profiles of active companies across the IVD landscape. -
M&A Activity Tracking
Updates on mergers, acquisitions, partnerships, and collaborations shaping the market. -
Industry & Region Watch
Analysis of regional and segment-specific trends to support tailored strategic planning. -
In-Depth News Analysis
Reporting on significant developments and events, including exclusive information not readily available elsewhere.
2026 Editorial Focus
Topics vary month to month, reflecting evolving industry priorities. In 2026, subscribers can expect issues dedicated to:
-
Reimbursement trends
-
Quality control reagents
-
Cardiac markers
-
STI point-of-care testing
-
Non-respiratory infectious diseases
-
An overall IVD market trend analysis
-
A forward-looking forecast of the respiratory testing market through 2027
- And more!
By delivering focused, actionable intelligence directly to subscribers’ each month, In Vitro Diagnostics Business Outlook helps decision-makers anticipate market shifts, identify growth opportunities, and navigate the complexities of the global IVD industry with confidence.
Table: Global Lab-Based Immunoassay Market, by Segment, 2026-2031 ($ million)
| Segment | 2026 | % Mkt | 2031 | % Mkt | CAGR |
| Allergy | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Anemia | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Autoimmune | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Blood Bank Screening | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Cardiac Markers | $XX Million | $XX Million | $XX Million | XX% | XX% |
| COVID-19 | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Diabetes/HbA1c | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Fertility | $XX Million | $XX Million | $XX Million | XX% | XX% |
| HAIs/Sepsis | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Hepatitis | $XX Million | $XX Million | $XX Million | XX% | XX% |
| HIV | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Lyme disease | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Mycology | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Parasitology | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Proteins | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Respiratory (excl. COVID) | $XX Million | $XX Million | $XX Million | XX% | XX% |
| STD | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Therapeutic Drugs | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Thyroid | $XX Million | $XX Million | $XX Million | XX% | XX% |
| ToRCH | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Tox/Drug of Abuse | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Tumor Markers | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Vitamin D | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Other Infectious Disease | $XX Million | $XX Million | $XX Million | XX% | XX% |
| Others Non-Infectious Disease | $XX Million | $XX Million | $XX Million | XX% | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
In Vitro Diagnostics Business Outlook, Volume 5, Issue 1 – Focus on Reimbursement
Market Analysis: Reimbursement
Overview of IVD Reimbursement
Outlook: Reimbursement
- Figure: CMS Average Reimbursement Trend: 40+ High-Frequency Clinical Laboratory Test Codes
- Table: CMS Reimbursement Limit by Clinical Laboratory Test Code, 2010, 2015, 2020, and 2025
- Table: Select Companies/Products Expected 2026 Reimbursement Impact
- Table: Summary of Key Reimbursement Drivers
Executive News Briefing
Briefings
Kiffik Biomedical Closes Series A Financing
NeoGenomics Appoints Jack Kenny to Board of Directors
Cardio Diagnostics Launches Precision CHD Test in India
Cyclomics Closes €2.5 Million Investment Round
Truvian Appoints New Chief Medical and Strategy Officer
Alamar Biosciences Closes $50 Million in New Capital
Alamar Biosciences Welcomes New CSO
Hummingbird Diagnostics Appoints New CEO
Precede Biosciences Nabs $83.5 Million in Total Financing
Financial Highlights
Agilent Full Year Fiscal 2025 Sales up 7% in Business YOY
- Figure: Agilent Sales by Business, FY 2024 and 2025 ($)
- Figure: Agilent Sales by Business, FY 2025 Quarterly Performance ($)
- Table: Agilent Revenue Mix, by Type, FY 2025 (%)
- Figure: Agilent FY 2025 Regional Sales Breakdown Distribution (%)
Diagnostic Market Mergers, Acquisitions, and Partnership Deals
Mergers and Acquisitions
- Table: Recent Diagnostic Market Mergers, Acquisitions, and Partnership Deals
Partnerships and Collaborations
Industry Watch
Industry Watch COVID-19/Flu Update
Region Watch
Australia
- Figure: Australia Exports, Distribution by Industry Segment, 2023 ($ billion)
- Figure: Australia IVD Market Sales Trend, 2020-2025 ($ million)
Broad-based Company Announcements
Announcements
Mira Precision Health Launches ToxNav in U.S.
Beckton Dickinson Receives FDA Clearance and CE Marking
QuidelOrtho Captures FDA Clearance or VITROS Immunodiagnostic
FDA Proposes Reclassification of Companion Diagnostic Assays
Congress Discusses PAMA
MeMed Accelerates AI-enabled Acute-Care Diagnostics
Truvian Health Snags Clearance for Nine Additional Analytes
Related products
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
Price range: $6,300.00 through $9,450.00
The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition
April 23, 2024
Explore the latest trends and forecasts in the point-of-care (POC) diagnostic tests market with Kalorama Information’s The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition. Discover the key growth areas and technological advancements shaping the future of POC diagnostics.
Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in…
Price range: $7,000.00 through $10,000.00
The IVD Market in South Korea, 2024
February 26, 2024
Gain valuable insights into South Korea’s in vitro diagnostics (IVD) market with Kalorama Information’s comprehensive report, The IVD Market in South Korea, 2024. We offer a detailed analysis of South Korea’s IVD revenues for 2023 and forecasts for 2028, segmented into key categories such as clinical chemistry, immunoassay, microbiology/molecular testing, point-of-care (POC),…
Price range: $5,000.00 through $7,875.00
